UnitedHealth Stock: Is Wall Street Bullish or Bearish?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2025
0mins
Source: NASDAQ.COM
Company Overview and Performance: UnitedHealth Group, a major health insurance provider, has seen its stock decline by 26.1% over the past year, significantly underperforming the S&P 500 and the iShares U.S. Healthcare Providers ETF due to unexpected increases in Medicare Advantage expenses and regulatory uncertainties.
Analyst Ratings and Future Outlook: Despite recent challenges, analysts maintain a "Strong Buy" consensus on UNH stock, with price targets suggesting potential upside of up to 76.9%, although expectations for earnings per share are projected to decline by 5.7% for the current fiscal year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNH
Wall Street analysts forecast UNH stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 272.280
Low
330.00
Averages
397.82
High
444.00
Current: 272.280
Low
330.00
Averages
397.82
High
444.00
About UNH
UnitedHealth Group Incorporated is a healthcare and well-being company. Its segments include Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. Optum Health offers comprehensive and patient-centered care, addressing the physical, mental, social, and financial well-being. Optum Health delivers primary, specialty and surgical care; helps patients and providers navigate and address complex, chronic and behavioral health needs. Optum Insight connects the healthcare system with services, analytics and platforms that make clinical, administrative and financial processes simpler and more efficient for all participants in the healthcare system. Optum Rx offers a range of pharmacy care services through retail pharmacies, through home delivery, specialty and community health pharmacies and the provision of in-home and community-based infusion services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVS Health Reaches Proposed Settlement with FTC on Insulin Pricing
- Settlement Progress: CVS Health's proposed settlement with the FTC is expected to be finalized in the coming weeks, modeled after a similar agreement with Cigna's Express Scripts, indicating the company's proactive stance on drug pricing transparency.
- Stock Price Reaction: Following the settlement news, CVS Health shares rose 2% on Tuesday, reflecting market optimism about the agreement, with analysts suggesting that this resolution will alleviate uncertainties in the pharmacy benefit management sector, thereby boosting investor confidence.
- Market Outlook: Leerink reiterated an 'Outperform' rating on CVS Health with a $98 price target, suggesting a potential upside of approximately 35% from Tuesday's closing price, indicating a positive market sentiment regarding the company's future performance.
- Cost Reduction for Patients: The settlement with the FTC is expected to lower patients' out-of-pocket costs for insulin and other drugs by up to $7 billion over the next decade, highlighting CVS's strategic importance in advocating for drug price rationalization.
See More
Delta Air Lines Defies Market Trends Amid Rising Costs
- Stock Performance: Despite the broader airline sector grappling with rising costs and geopolitical fragmentation, Delta Air Lines (DAL) maintains a share price above $63, reflecting a nearly 70% increase since December 1st, showcasing its relative resilience in the market.
- Fuel Cost Pressure: Delta's management has flagged a $400 million increase in fuel expenses for Q1 2026, and while the company has raised revenue guidance to counter this challenge, relying on 'record bookings' to offset fuel costs poses significant risks.
- Competitive Landscape: In stark contrast to Delta, peers like American Airlines (AAL) and Southwest Airlines (LUV) have seen their valuations compressed under the 'Crack Spread Paradox', indicating that Delta's 'priced for perfection' status may be difficult to sustain.
- Strategic Investment Advice: For investors seeking exposure to the airline industry, it is advisable to consider protective strategies, such as selling call options to hedge against potential stock price declines, especially given the ongoing geopolitical and energy crisis uncertainties.
See More
Healthcare Stocks Long-Term Investors Should Buy Now
- Pfizer's Recovery Potential: Pfizer (PFE) previously achieved a staggering $100 billion in revenue, but has seen significant declines due to reduced demand for COVID products and patent expirations, with a current price-to-earnings ratio of only 9, making it attractive for long-term investors.
- Growth Driven by Acquisitions: Pfizer's acquisitions of Seagen and Metsera have provided it with commercialized drugs and late-stage candidates, positioning the company to enter the high-growth oncology and obesity drug markets, thereby laying the groundwork for future growth.
- UnitedHealth Group's Strategic Actions: UnitedHealth Group (UNH) has faced challenges from rising healthcare costs and increased service usage, but has implemented measures such as cutting certain plans and utilizing AI to streamline processes, which are expected to aid recovery and growth in the coming quarters.
- Competitive Advantage and Investment Opportunity: UnitedHealth's dual business model in health insurance and health services provides a solid competitive moat, and with a current price-to-earnings ratio of 15, it presents a fantastic buying opportunity for investors, especially amid market fluctuations.
See More
Pfizer and UnitedHealth's Path to Recovery
- Pfizer's Growth Potential: Pfizer's revenue soared to an astonishing $100 billion a few years ago, but has significantly dropped due to declining demand for COVID products and patent expirations; however, through acquisitions of Seagen and Metsera, Pfizer is paving the way for growth in oncology and obesity drug markets.
- UnitedHealth's Transformation Measures: As the largest health insurer in the U.S., UnitedHealth has faced challenges from rising healthcare costs and increased service usage, but has implemented measures such as cutting certain plans and using AI to streamline processes, which are expected to aid recovery in the coming quarters.
- Investment Value Analysis: Pfizer is currently trading at only 9 times forward earnings estimates, indicating strong appeal for long-term investors, while UnitedHealth's trading at 15 times forward earnings presents an excellent buying opportunity, especially as the company takes proactive steps to improve performance.
- Long-Term Investment Strategy: For long-term investors, selecting companies like Pfizer and UnitedHealth that are currently facing challenges but have recovery potential allows for entry at reasonable prices and the opportunity to reap substantial returns as these companies regain growth, highlighting the strategic value of holding investments over the long term.
See More
Medicare Advantage Plans Under Cost Control Pressure Ahead of 2027 Rates
- Cost Control Issues: CMS Deputy Administrator Chris Klomp highlighted that Medicare Advantage plans have not effectively controlled costs, adding pressure to the upcoming 2027 reimbursement rate decision, which could impact insurers' profitability.
- Reimbursement Rate Proposal: The CMS's proposed flat reimbursement rates for MA insurers in January led to declines in managed care stocks, including UnitedHealth (UNH) and Humana (HUM), reflecting market concerns about future profitability amid regulatory changes.
- UnitedHealth's Response Strategy: As the largest MA insurer, UnitedHealth indicated it might consider benefit reductions in response to the CMS's “disappointing” initial reimbursement rates, showcasing the company's adaptability and strategic planning in the face of policy shifts.
- Market Choice Risks: Klomp warned that if the CMS acts “too aggressively” on rates, it could lead to plans exiting certain markets, thereby reducing choices for Medicare recipients and exacerbating market uncertainties.
See More
UnitedHealth Group Faces Rising Costs and Medicare Reform
- Stock Volatility: UnitedHealth Group's stock has dropped approximately 35% in 2025 and continued to decline over 13% in 2026, reflecting market concerns about its future prospects, although its low valuation suggests significant upside potential.
- Medicare Advantage Adjustment: The company plans to scale back some Medicare Advantage plans, aiming to streamline operations and reduce costs, with expectations that these measures will enhance operational efficiency and pave the way for future profit growth.
- Revenue Expectations: Revenue is projected to dip slightly from $447.6 billion in 2025 to $439 billion in 2026; however, earnings are expected to return to growth, demonstrating resilience in its profitability.
- Market Competitiveness: Despite facing negative publicity and potential flat Medicare payment rates, UnitedHealth Group remains one of the world's largest healthcare companies, with its dominant position in insurance and care largely intact.
See More
CVS Health Reaches Proposed Settlement with FTC on Insulin Pricing
- Settlement Progress: CVS Health's proposed settlement with the FTC is expected to be finalized in the coming weeks, modeled after a similar agreement with Cigna's Express Scripts, indicating the company's proactive stance on drug pricing transparency.
- Stock Price Reaction: Following the settlement news, CVS Health shares rose 2% on Tuesday, reflecting market optimism about the agreement, with analysts suggesting that this resolution will alleviate uncertainties in the pharmacy benefit management sector, thereby boosting investor confidence.
- Market Outlook: Leerink reiterated an 'Outperform' rating on CVS Health with a $98 price target, suggesting a potential upside of approximately 35% from Tuesday's closing price, indicating a positive market sentiment regarding the company's future performance.
- Cost Reduction for Patients: The settlement with the FTC is expected to lower patients' out-of-pocket costs for insulin and other drugs by up to $7 billion over the next decade, highlighting CVS's strategic importance in advocating for drug price rationalization.
See More
Delta Air Lines Defies Market Trends Amid Rising Costs
- Stock Performance: Despite the broader airline sector grappling with rising costs and geopolitical fragmentation, Delta Air Lines (DAL) maintains a share price above $63, reflecting a nearly 70% increase since December 1st, showcasing its relative resilience in the market.
- Fuel Cost Pressure: Delta's management has flagged a $400 million increase in fuel expenses for Q1 2026, and while the company has raised revenue guidance to counter this challenge, relying on 'record bookings' to offset fuel costs poses significant risks.
- Competitive Landscape: In stark contrast to Delta, peers like American Airlines (AAL) and Southwest Airlines (LUV) have seen their valuations compressed under the 'Crack Spread Paradox', indicating that Delta's 'priced for perfection' status may be difficult to sustain.
- Strategic Investment Advice: For investors seeking exposure to the airline industry, it is advisable to consider protective strategies, such as selling call options to hedge against potential stock price declines, especially given the ongoing geopolitical and energy crisis uncertainties.
See More
Healthcare Stocks Long-Term Investors Should Buy Now
- Pfizer's Recovery Potential: Pfizer (PFE) previously achieved a staggering $100 billion in revenue, but has seen significant declines due to reduced demand for COVID products and patent expirations, with a current price-to-earnings ratio of only 9, making it attractive for long-term investors.
- Growth Driven by Acquisitions: Pfizer's acquisitions of Seagen and Metsera have provided it with commercialized drugs and late-stage candidates, positioning the company to enter the high-growth oncology and obesity drug markets, thereby laying the groundwork for future growth.
- UnitedHealth Group's Strategic Actions: UnitedHealth Group (UNH) has faced challenges from rising healthcare costs and increased service usage, but has implemented measures such as cutting certain plans and utilizing AI to streamline processes, which are expected to aid recovery and growth in the coming quarters.
- Competitive Advantage and Investment Opportunity: UnitedHealth's dual business model in health insurance and health services provides a solid competitive moat, and with a current price-to-earnings ratio of 15, it presents a fantastic buying opportunity for investors, especially amid market fluctuations.
See More
Pfizer and UnitedHealth's Path to Recovery
- Pfizer's Growth Potential: Pfizer's revenue soared to an astonishing $100 billion a few years ago, but has significantly dropped due to declining demand for COVID products and patent expirations; however, through acquisitions of Seagen and Metsera, Pfizer is paving the way for growth in oncology and obesity drug markets.
- UnitedHealth's Transformation Measures: As the largest health insurer in the U.S., UnitedHealth has faced challenges from rising healthcare costs and increased service usage, but has implemented measures such as cutting certain plans and using AI to streamline processes, which are expected to aid recovery in the coming quarters.
- Investment Value Analysis: Pfizer is currently trading at only 9 times forward earnings estimates, indicating strong appeal for long-term investors, while UnitedHealth's trading at 15 times forward earnings presents an excellent buying opportunity, especially as the company takes proactive steps to improve performance.
- Long-Term Investment Strategy: For long-term investors, selecting companies like Pfizer and UnitedHealth that are currently facing challenges but have recovery potential allows for entry at reasonable prices and the opportunity to reap substantial returns as these companies regain growth, highlighting the strategic value of holding investments over the long term.
See More
Medicare Advantage Plans Under Cost Control Pressure Ahead of 2027 Rates
- Cost Control Issues: CMS Deputy Administrator Chris Klomp highlighted that Medicare Advantage plans have not effectively controlled costs, adding pressure to the upcoming 2027 reimbursement rate decision, which could impact insurers' profitability.
- Reimbursement Rate Proposal: The CMS's proposed flat reimbursement rates for MA insurers in January led to declines in managed care stocks, including UnitedHealth (UNH) and Humana (HUM), reflecting market concerns about future profitability amid regulatory changes.
- UnitedHealth's Response Strategy: As the largest MA insurer, UnitedHealth indicated it might consider benefit reductions in response to the CMS's “disappointing” initial reimbursement rates, showcasing the company's adaptability and strategic planning in the face of policy shifts.
- Market Choice Risks: Klomp warned that if the CMS acts “too aggressively” on rates, it could lead to plans exiting certain markets, thereby reducing choices for Medicare recipients and exacerbating market uncertainties.
See More
UnitedHealth Group Faces Rising Costs and Medicare Reform
- Stock Volatility: UnitedHealth Group's stock has dropped approximately 35% in 2025 and continued to decline over 13% in 2026, reflecting market concerns about its future prospects, although its low valuation suggests significant upside potential.
- Medicare Advantage Adjustment: The company plans to scale back some Medicare Advantage plans, aiming to streamline operations and reduce costs, with expectations that these measures will enhance operational efficiency and pave the way for future profit growth.
- Revenue Expectations: Revenue is projected to dip slightly from $447.6 billion in 2025 to $439 billion in 2026; however, earnings are expected to return to growth, demonstrating resilience in its profitability.
- Market Competitiveness: Despite facing negative publicity and potential flat Medicare payment rates, UnitedHealth Group remains one of the world's largest healthcare companies, with its dominant position in insurance and care largely intact.
See More
